Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Revenue (2018 - 2025)

BioNexus Gene Lab's Revenue history spans 8 years, with the latest figure at $483760.0 for Q4 2025.

  • Quarterly results put Revenue at $483760.0 for Q4 2025, down 80.83% from a year ago — trailing twelve months through Dec 2025 was $7.4 million (down 21.93% YoY), and the annual figure for FY2025 was $7.4 million, down 21.93%.
  • Revenue for Q4 2025 was $483760.0 at BioNexus Gene Lab, down from $2.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $3.6 million in Q3 2021 to a low of $483760.0 in Q4 2025.
  • The 5-year median for Revenue is $2.5 million (2023), against an average of $2.5 million.
  • The sharpest move saw Revenue skyrocketed 180.21% in 2021, then tumbled 80.83% in 2025.
  • Year by year, Revenue stood at $3.2 million in 2021, then dropped by 12.5% to $2.8 million in 2022, then dropped by 19.95% to $2.3 million in 2023, then rose by 11.03% to $2.5 million in 2024, then tumbled by 80.83% to $483760.0 in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $483760.0, $2.5 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.